What is Selenase T?
Selenase T is mineral that is found in soil and occurs naturally in certain foods (such as whole grains, Brazil nuts, sunflower seeds, and seafood). Selenase T is not produced in the body, but it is needed for proper thyroid and immune system function.
Selenase T is used to treat or prevent Selenase T deficiency.
Selenase T has been used in alternative medicine as an aid to treat Hashimoto's thyroiditis (an autoimmune disorder of the thyroid), and to treat high cholesterol.
Not all uses for Selenase T have been approved by the FDA. Selenase T should not be used in place of medication prescribed for you by your doctor.
Selenase T may also be used for purposes not listed in this product guide.
Selenase T indications
Oral
Selenase T deficiency
Adult: 100-500 mcg of Selenase T daily.
Intramuscular
Selenase T deficiency
Adult: 100-500 mcg of Selenase T daily.
Intravenous
Selenase T deficiency
Adult: 100-500 mcg of Selenase T daily.
Uses of Selenase T in details
Selenase T is used as a dietary supplement mainly in the treatment of Selenase T deficiency affecting young women and children with Keshan disease. It is also used for treatment of osteoarthiritis associated with poor Selenase T levels in body called Kashin-Beck Disease. Selenase T supplements are also used in patients with HIV/ AIDS to maintain the adequate Selenase T levels.
Selenase T dosage
Selenase T Injection provides 40 mcg Selenase T/mL. For metabolically stable adults receiving TPN, the suggested additive dosage level is 20 to 40 mcg Selenase T/day. For pediatric patients, the suggested additive dosage level is 3 mcg/kg/day.
In adults, Selenase T deficiency states resulting from long-term TPN support, Selenase T as selenomethionine or selenious acid, administered intravenously at 100 mcg/day for a period of 24 and 31 days, respectively, has been reported to reverse deficiency symptoms without toxicity.
Aseptic addition of Selenase T Injection to the TPN solution under laminar flow hood is recommended. Selenase T is physically compatible with the electrolytes and other trace elements usually present in amino-acid/dextrose solution used for TPN. Frequent monitoring of plasma Selenase T levels is suggested as a guideline for subsequent administration. The normal whole blood range for Selenase T is approximately 10 to 37 mcg/100 mL.
Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.
Selenase T interactions
See also:
What other drugs will affect Selenase T?
Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination
Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Consider therapy modification
Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification
Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification
Dolutegravir: Selenase T may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral Selenase T. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral Selenase T. Consider therapy modification
Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification
Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification
PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification
Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Consider therapy modification
Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification
Selenase T side effects
See also:
What are the possible side effects of Selenase T?
No Selenase T-related adverse reactions have been reported in clinical studies or postmarketing reports in patients receiving intravenously administered PN solutions containing selenious acid within the recommended dosage range.
The following adverse reactions associated with use of other components of PN solutions were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
- Pulmonary embolism due to pulmonary vascular precipitates
- Vein damage and thrombosis
- Aluminum toxicity
Selenase T contraindications
See also:
What is the most important information I should know about Selenase T?
Selenase T Injection should not be given undiluted by direct injection into a peripheral vein because of the potential for infusion phlebitis.
Active ingredient matches for Selenase T:
Sodium Selenite in Germany.
List of Selenase T substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Selenase (Austria, Czech Republic, Germany, Netherlands, Switzerland, Turkey) | |
Solution; Oral; Selenium / Sodium Selenite 166.5 mcg / ml (Biosyn) | |
Selenase 100 µg/2 ml (Austria) | |
selenase 100μg (Germany) | |
selenase 300 RP (Germany) | |
selenase 50 (Germany) | |
selenase 50 AP (Germany) | |
Selenase 50 µg/ml (Austria) | |
Selenase 500 µg/10 ml (Austria) | |
selenase AP (Germany) | |
selenase RP (Germany) | |
Selenio Jenson (Italy) | |
Sélénium (France) | |
Tablet; Oral; Selenium 50 mcg | |
Tablet; Oral; Selenium / Yeast 200 mcg | |
Tablet; Oral; Selenium / Yeast 50 mcg | |
Tablet; Oral; Selenium / Selenium HVP Chelate 200 mcg | |
Tablet; Oral; Selenium / Sodium Selenite 200 mcg | |
Tablet; Oral; Selenium / Yeast 100 mcg | |
Tablet, Extended Release; Oral; Selenium 50 mcg | |
Drug Premix; Oral; Selenium / Sodium Selenite 10 g / kg | |
Drug Premix; Oral; Selenium / Sodium Selenite 200 mg / kg | |
Tablet; Oral; Selenium 200 mcg | |
Drops; Oral; Selenium 4 ch | |
Tablet; Oral; Selenium / Selenium HVP Chelate 100 mcg | |
Capsule; Oral; Selenium / Sodium Selenite 30 mcg | |
Capsule; Oral; Selenium / Selenium HVP Chelate 200 mcg | |
Capsule; Oral; Selenium / Selenium HVP Chelate 100 mcg | |
Tablet; Oral; Selenium 10 x | |
Tablet; Oral; Selenium / Selenium Yeast 200 mcg | |
Injectable; Injection; Selenium / Sodium Selenite 10 mcg / ml | |
Drug Premix; Oral; Selenium / Sodium Selenite 100 mg / kg | |
Drops; Oral; Selenium 3 ch | |
Selenium Aguettant (Belgium, United Kingdom) | |
Selenium AgVantage (Australia) | |
Sélénium Oligosol (France) | |
Aerosol with propellants; Oral; Selenium / Sodium Selenite 50 mcg / ml | |
Selenium Oral Concentrate (Australia) | |
Selesyn 500 µg (Hungary) | |
Seltec (New Zealand) | |
Seltrans (Germany) | |
Sodium Selenite (Austria, Czech Republic, Germany, Netherlands, Switzerland, Turkey) | |
Solution; Oral; Sodium Selenite 200 mcg / 5 ml | |
Tas Sel (New Zealand) | |
Uniselen (Germany) | |
See 56 substitutes for Selenase T |
Reviews
The results of a survey conducted on ndrugs.com for Selenase T are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Selenase T. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology